Mike Grey, President and Chief Executive Officer
Stephen K. Burley, M.D., D. Phil., F.R.S.C., Chief Scientific Officer and Senior Vice President, Research
Kristine Figueroa, C.C.P., Sr. Director, Human Resources
W. Todd Myers, C.P.A. Chief Financial Officer
Annette North, Esq., General Counsel
Siegfried Reich, Ph.D., Vice President, Drug Discovery
Terry Rugg, M.D., Chief Medical Officer and Vice President, Development
Mike Grey joined us in September 2001 as our Executive Vice President and Chief Business Officer and as a member of our board of directors. He became our President in June 2003 and our Chief Executive Officer in January 2005. Prior to joining us, Mike served as a director of Trega Biosciences, Inc., a biopharmaceutical company acquired by Lion bioscience AG in 2001, from December 1998 to March 2001. He was also the President and Chief Executive Officer of Trega Biosciences, Inc. from January 1999 to March 2001. Prior to joining Trega, Mike was the President of BioChem Therapeutic, Inc., the pharmaceutical operating division of BioChem Pharma Inc., from 1994 to 1998. In that role, he was responsible for all company operations including research, development, sales and marketing, finance and human resources. During 1994, Mike was the President and Chief Operating Officer for Ansan, Inc. From 1974 to 1993, Mike served in various roles with Glaxo Inc. and Glaxo Holdings, plc, culminating in his position as Vice President, Corporate Development. Mike serves as a director of Achillion Pharmaceuticals, Inc., IDM Pharma, Inc. (formerly known as Epimmune Inc.) and BioMarin Pharmaceutical, Inc. Mike received a B.Sc. in Chemistry from the University of Nottingham, United Kingdom.
Top
Stephen K. Burley, M.D., D.Phil., joined us in February 2002 as our Chief Scientific Officer and Senior Vice President, Research. Stephen has been an Adjunct Professor at The Rockefeller University since February 2002, where he was also the Richard M. and Isabel P. Furlaud Professor from June 1997 to January 2002. He was an Investigator at the Howard Hughes Medical Institute from September 1994 to January 2002. He was previously the Principal Investigator of the New York Structural Genomics Research Consortium. Stephen is a Fellow of the Royal Society of Canada and of the New York Academy of Sciences. His research focused on the macromolecular machines responsible for mRNA transcription, splicing and translation in eukaryotes and on the problem of antibiotic resistance. Stephen received an M.D. degree from Harvard Medical School and, as a Rhodes Scholar, he received a D.Phil. in Molecular Biophysics from Oxford University. His clinical training combined a residency in Internal Medicine at the Brigham and Women's Hospital with postdoctoral work in protein crystallography under the direction of William N. Lipscomb at Harvard University. He received a B.Sc. in Physics from the University of Western Ontario. In 1999, Stephen co-founded Prospect Genomics, Inc., a San Francisco-based drug discovery company that we acquired in May 2001.
Top
Kristine Figueroa, C.C.P., joined us in May 2006 as Sr. Director, Human Resources. Prior to joining us, she held the position of Director, Human Resources at Kintera, Inc., a software service provider, overseeing the Human Resources function. From 1998 to 2005, Kristine worked at Elan Pharmaceuticals (acquirer of Dura Pharmaceuticals), a neuroscience-based biotechnology company, most recently in the position of Associate Director, Total Rewards. Prior to joining Elan, Kristine was employed with Intuit, a personal finance and small business software solution provider, from 1996 to 1998. Kristine has held roles as a Business Partner and Compensation professional during her years of experience as a Human Resources professional. Kristine holds a B.S. in Business Administration and a M.S. in Human Resources Management from Troy State University.
Top
W. Todd Myers, C.P.A., joined us as our Chief Financial Officer in December 2005. Prior to joining us, Todd provided senior-level financial consulting services to publicly traded and privately held life science companies from October 2004 to December 2005. From March 2000 to June 2004, Todd was Chief Financial Officer, Secretary and Treasurer of FeRx Incorporated, a clinical development stage company dedicated to the development of oncology products based on a patented drug-delivery technology. From June 1997 to February 2000, he was Director of Finance at CombiChem, Inc., a publicly traded computational drug discovery company that was acquired by DuPont in 1999. Todd has also held positions with Premier Inc., a national consortium of health care providers, and with Ernst & Young, LLP. Todd received his B.S. in Accounting from the University of Illinois.
Top
Annette North, Esq., joined us in November 2000 as our Corporate Counsel and was appointed Vice President, Legal Affairs in January 2004. Prior to joining us, she was Senior Director of Operations and Legal at Axys Pharmaceuticals, Inc., a small molecule drug discovery company, from 1998 to 1999 and Legal Counsel and Director of Legal Affairs at Sequana Therapeutics, Inc., a biotechnology company, from 1995 to 1998. From 1991 to 1994, Annette was employed by Nabarro Nathanson plc, a national law firm in London, England, focusing primarily on commercial litigation, and from 1989 to 1990 she worked at Corrs, Chambers, Westgarth, a national law firm in Melbourne, Australia. She is a member of the State Bar of California, a Solicitor of the Supreme Court of England and Wales and a Barrister and Solicitor of the Supreme Court of Victoria, Australia. Annette received both her Bachelor of Commerce and her Bachelor of Laws from the University of Melbourne, Australia.
Top
Siegfried Reich, Ph.D., joined us in January 2006 as Vice President of Drug Discovery. Prior to joining us, from 2001 to December 2005, Siegfried was Vice President, Head of Viral and Ophthalmic Diseases Therapeutic Zone in Discovery at Pfizer, Inc. (Global Research and Development, La Jolla), overseeing the development of multiple clinical candidates in antivirals and ophthalmology. Prior to that, Siegfried held the position of Director, Head of Medicinal Chemistry at Agouron Pharmaceuticals, Inc., from 1997 to 2001 (through its acquisitions by Warner Lambert and Warner Lambert's subsequent acquisition by Pfizer, Inc.). He began work at Agouron as a research scientist in 1988, and served as a project chemist and co-project leader of the HIV Protease Project, which identified ViraceptR, Agouron's first approved drug for the treatment of AIDS, for which he is also an inventor. Siegfried received his B.S. in Chemistry in 1982 from San Diego State University and his Ph.D. in Chemistry in 1986 from the University of California, Irvine.
Top
Terry Rugg, M.D., joined us in August 2006 as Chief Medical Officer (CMO) and Vice President of Development. Terry is an Oncologist with 16 years of cancer specific industry experience; having occupied international and US focused positions in both large and small pharmaceutical companies, including Eli Lilly and Company, Zeneca Pharmaceuticals, Ilex Oncology and British Biotech. Terry commenced his career with Eli Lilly, and played a key role in the successful development of Gemzar® (gemcitabine) for small cell lung cancer and pancreatic cancer. Beyond gemcitabine, Terry has been intimately involved in the development and successful registration of both Campath® (CD52 targeted monoclonal antibody indicated for CLL) and Clolar® (clofarabine), indicated in pediatric leukemias. Terry also has extensive FDA (IND, NDA and BLA), EMEA (CTX, DDX and MAA) and other regulatory experience, and most recently, Medical Affairs experience. Terry joins us from Sanofi-Aventis, where he held the Vice President position of Head of Oncology, Global Medical Affairs (Aventis) and more recently, Head of Oncology, US Medical Affairs (Sanofi-Aventis) where he led a department of approximately 59 Regional and National Liaisons and MDs. Terry received his M.D. from the University of Rhodesia, Godfrey Higgins School of Medicine and Surgery.
Top
|
|
